Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome

HIV Medicine

Volumn 9, Issue 6, 2008, Pages 440-444

  Voirin, N ^a,b,c   Routy, J P ^d   Smith, D ^e   Baratin, D ^c   Trepo C ^a,f,g   Cotte, L ^a,f,g   Touraine, J L ^c   Livrozet, J M ^c   Cooper, D A ^e   Ritter, J ^a,h   Andre P ^a,h   Vanhems, Philippe ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f HÔTEL DIEU   (France)

^g INSERM   (France)

^h CROIX ROUSSE HOSPITAL   (France)

Author keywords

Acute disease; CD4 lymphocyte count; Highly active antiretroviral therapy; HIV infections; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACUTE RETROVIRAL SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 47649087769     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00576.x     Document Type: Article

References (15)

1. Hecht FM, Wang L, Collier A et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194: 725-733.
2. Kinloch-de Loes S. Treatment of acute HIV-1 infection: Is it coming of age? J Infect Dis 2006; 194: 721-724.
3. Streeck H, Jessen H, Alter G et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006; 194: 734-739.
4. Alter G, Tsoukas CM, Rouleau D et al. Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection. AIDS 2004; 18: 1979-1989.
5. Dion ML, Bordi R, Zeidan J et al. Slow disease progression and robust therapy-mediated CD4 T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 2007; 109: 2912-2920.
6. Brenner BG, Roger M, Routy JP et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195: 951-959.
7. Smith DE, Kaufmann GR, Kahn JO et al. Greater reversal of CD4 cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003; 19: 189-199.
8. Vanhems P, Hughes J, Collier AC et al. Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney. AIDS 2000; 14: 375-381.
9. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007; 186: 146-151.
10. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy 2006; 26: 1111-1133.
11. Lichterfeld M, Yu XG, Mui SK et al. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8 T cells after early HIV-1 infection. J Virol 2007; 81: 4199-4214.
12. Oxenius A, Price DA, Easterbrook PJ et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8 and CD4 T lymphocytes. Proc Natl Acad Sci USA 2000; 97: 3382-3387.
13. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10: 806-810.
14. Ngo-Giang-Huong N, Deveau C, Da Silva I et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15: 665-673.
15. Vanhems P, Lambert J, Cooper DA et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: A dose-response relationship. Clin Infect Dis 1998; 26: 323-329.